{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:24:51Z","timestamp":1787855091288,"version":"build-2784847793"},"reference-count":45,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0146_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Dihydropyrimidine dehydrogenase (DPD) phenotyping through uracil and dihydrouracil determination is a well-established approach to identify (partial) DPD deficiencies prior to fluoropyrimidine chemotherapy. However, preanalytical stability has challenged this test for years. This study therefore investigated whether dried blood spots (DBS) can improve preanalytical stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0146_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Uracil, dihydrouracil, and uridine were determined in 6\u202fmm DBS sub-punch extracts by liquid chromatography-tandem mass spectrometry. Paired venous and capillary DBS were collected from 15 healthy volunteers across three days to evaluate venous-capillary DBS differences. The impact of blood spotting, drying and preanalytical stability for up to two weeks was assessed using venous DBS of the same volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0146_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Uracil was elevated in all capillary DBS, with a median of 219\u202f% relative to venous DBS. In addition, the variation between capillary DBS replicates was 29\u202f%, opposed to only 7\u202f% in venous DBS. For dihydrouracil, a small bias of\u00a0\u22127\u202f% was observed, while uridine showed no difference, with similar inter-spot variation in venous and capillary DBS. Generation and drying of DBS had statistically significant yet minor effects on all analytes. Venous DBS enhanced preanalytical stability, yielding median uracil levels of 105\u202f% and 107\u202f% after 1 and 2\u00a0weeks at room temperature, and no differences for dihydrouracil or uridine relative to overnight dried\u00a0DBS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0146_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Capillary DBS are unsuitable for uracil determination in DPD phenotyping owing to poor agreement with venous DBS and substantial variability. Venous DBS, however, demonstrate superior preanalytical stability over liquid samples and may provide a practical solution for managing preanalytical variables.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0146","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:00:46Z","timestamp":1777971646000},"page":"2275-2285","source":"Crossref","is-referenced-by-count":0,"title":["Capillary dried blood microsampling is not suited for dihydropyrimidine dehydrogenase (DPD) phenotyping"],"prefix":"10.1515","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-0854","authenticated-orcid":false,"given":"Kevin","family":"Vandenbroucke","sequence":"first","affiliation":[{"name":"Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences , Ghent University , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig","family":"Stepman","sequence":"additional","affiliation":[{"name":"Laboratory of Metabolic Diseases, Department of Laboratory Medicine , Ghent University Hospital , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-348X","authenticated-orcid":false,"given":"Christophe","family":"Stove","sequence":"additional","affiliation":[{"name":"Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences , Ghent University , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026082718023500057_j_cclm-2026-0146_ref_001","doi-asserted-by":"crossref","unstructured":"Detailleur, S, Segelov, E, Re, MD, Prenen, H. Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. Ann Gastroenterol 2021;34:68\u201372. https:\/\/doi.org\/10.20524\/aog.2020.0551.","DOI":"10.20524\/aog.2020.0551"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_002","doi-asserted-by":"crossref","unstructured":"Abiodun, AT, Ju, C, Welch, CA, Lai, J, Tyrer, F, Chambers, P, et al.. Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer. JACC CardioOncol 2025. https:\/\/doi.org\/10.1016\/j.jaccao.2025.01.019.","DOI":"10.1016\/j.jaccao.2025.01.019"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_003","doi-asserted-by":"crossref","unstructured":"Barin-Le Guellec, C, Lafay-Chebassier, C, Ingrand, I, Tournamille, JF, Boudet, A, Lanoue, MC, et al.. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France. Eur J Cancer 2020;124:37\u201346. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.028.","DOI":"10.1016\/j.ejca.2019.09.028"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_004","doi-asserted-by":"crossref","unstructured":"Henricks, LM, Lunenburg, C, de Man, FM, Meulendijks, D, Frederix, GWJ, Kienhuis, E, et al.. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:1459\u201367. https:\/\/doi.org\/10.1016\/s1470-2045(18)30686-7.","DOI":"10.1016\/S1470-2045(18)30686-7"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_005","doi-asserted-by":"crossref","unstructured":"van Kuilenburg, AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004.","DOI":"10.1016\/j.ejca.2003.12.004"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_006","doi-asserted-by":"crossref","unstructured":"Zaanan, A, Pallet, N, Narjoz, C, Loriot, MA, Hafliger, \u00c9. A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen. Eur J Cancer 2024;205:114102. https:\/\/doi.org\/10.1016\/j.ejca.2024.114102.","DOI":"10.1016\/j.ejca.2024.114102"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_007","doi-asserted-by":"crossref","unstructured":"Etienne-Grimaldi, MC, Pallet, N, Boige, V, Ciccolini, J, Chouchana, L, Barin-Le Guellec, C, et al.. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. Eur J Cancer 2023;181:3\u201317. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.028.","DOI":"10.1016\/j.ejca.2022.11.028"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_008","doi-asserted-by":"crossref","unstructured":"Amstutz, U, Henricks, LM, Offer, SM, Barbarino, J, Schellens, JHM, Swen, JJ, et al.. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018;103:210\u20136. https:\/\/doi.org\/10.1002\/cpt.911.","DOI":"10.1002\/cpt.911"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_009","unstructured":"INCa and HAS. Recherche de d\u00e9ficit en dihydropyrimidine d\u00e9shydrogenase en vue de pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res survenant sous traitement comportant des fluoropyrimidines (5-fluorouracile): recommandations et r\u00e9f\u00e9rentiels, INCa, HAS 2018."},{"key":"2026082718023500057_j_cclm-2026-0146_ref_010","unstructured":"Houssiau, H, Duck, L, Carlier, S. A case of life-threatening toxicity following capecitabine treatment: advocacy for dihydropyrimidine dehydrogenase deficiency screening. Belg J Med Oncol 2020;14:151\u20134."},{"key":"2026082718023500057_j_cclm-2026-0146_ref_011","doi-asserted-by":"crossref","unstructured":"Casneuf, V, Borbath, I, Van den Eynde, M, Verheezen, Y, Demey, W, Verstraete, AG, et al.. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clin Belg 2022;77:346\u201352. https:\/\/doi.org\/10.1080\/17843286.2020.1870855.","DOI":"10.1080\/17843286.2020.1870855"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_012","doi-asserted-by":"crossref","unstructured":"Meulendijks, D, Henricks, LM, Jacobs, BAW, Aliev, A, Deenen, MJ, de Vries, N, et al.. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 2017;116:1415\u201324. https:\/\/doi.org\/10.1038\/bjc.2017.94.","DOI":"10.1038\/bjc.2017.94"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_013","doi-asserted-by":"crossref","unstructured":"B\u00fcchel, B, Rhyn, P, Sch\u00fcrch, S, B\u00fchr, C, Amstutz, UR, Largiad\u00e8r, C. LC-MS\/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr 2013;27:7\u201316. https:\/\/doi.org\/10.1002\/bmc.2741.","DOI":"10.1002\/bmc.2741"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_014","doi-asserted-by":"crossref","unstructured":"Coudor\u00e9, F, Roche, D, Lefeuvre, S, Faussot, D, Billaud, EM, Loriot, M-A, et al.. Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. J\u00a0Chromatogr Sci 2012;50:877\u201384. https:\/\/doi.org\/10.1093\/chromsci\/bms085.","DOI":"10.1093\/chromsci\/bms085"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_015","doi-asserted-by":"crossref","unstructured":"Jacobs, BA, Rosing, H, de Vries, N, Meulendijks, D, Henricks, LM, Schellens, JH, et al.. Development and validation of a rapid and sensitive UPLC-MS\/MS method for determination of uracil and dihydrouracil in human plasma. J\u00a0Pharm Biomed Anal 2016;126:75\u201382. https:\/\/doi.org\/10.1016\/j.jpba.2016.04.039.","DOI":"10.1016\/j.jpba.2016.04.039"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_016","doi-asserted-by":"crossref","unstructured":"Robin, T, Saint-Marcoux, F, Toinon, D, Tafzi, N, Marquet, P, El Balkhi, S. Automatic quantification of uracil and dihydrouracil in plasma.\u00a0J\u00a0Chromatogr B Analyt Technol Biomed Life Sci 2020;1142:122038. https:\/\/doi.org\/10.1016\/j.jchromb.2020.122038.","DOI":"10.1016\/j.jchromb.2020.122038"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_017","doi-asserted-by":"crossref","unstructured":"Tafzi, N, Woillard, JB, Fleytoux, A, Picard, N, Marquet, P. Phenotyping of uracil and 5-fluorouracil metabolism using LC-MS\/MS for prevention of toxicity and dose adjustment of fluoropyrimidines. Ther Drug Monit 2020;42:540\u20137. https:\/\/doi.org\/10.1097\/ftd.0000000000000768.","DOI":"10.1097\/FTD.0000000000000768"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_018","doi-asserted-by":"crossref","unstructured":"Chavani, O, Jensen, BP, Strother, RM, Florkowski, CM, George, PM. Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, \u03b1-fluoro-\u03b2-ureidopropionic acid and \u03b1-fluoro-\u03b2-alanine in human plasma. J\u00a0Pharm Biomed Anal 2017;142:125\u201335. https:\/\/doi.org\/10.1016\/j.jpba.2017.04.055.","DOI":"10.1016\/j.jpba.2017.04.055"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_019","doi-asserted-by":"crossref","unstructured":"de With, M, Knikman, J, de Man, FM, Lunenburg, C, Henricks, LM, van Kuilenburg, ABP, et al.. Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Pharmacol Ther 2022;112:62\u20138. https:\/\/doi.org\/10.1002\/cpt.2608.","DOI":"10.1002\/cpt.2608"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_020","doi-asserted-by":"crossref","unstructured":"Maillard, M, Launay, M, Royer, B, Guitton, J, Gautier-Veyret, E, Broutin, S, et al.. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol 2023;89:762\u201372. https:\/\/doi.org\/10.1111\/bcp.15536.","DOI":"10.1111\/bcp.15536"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_021","doi-asserted-by":"crossref","unstructured":"Thomas, F, Launay, M, Guitton, J, Loriot, MA, Boyer, JC, Haufroid, V, et al.. Plasma uracil as a DPD phenotyping test: pre-analytical handling matters. Clin Pharmacol Ther 2023;113:471\u20132. https:\/\/doi.org\/10.1002\/cpt.2772.","DOI":"10.1002\/cpt.2772"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_022","doi-asserted-by":"crossref","unstructured":"van den Wildenberg, SAH, Streng, AS, van den Broek, R, Broeren, MAC, Deenen, MJ, van Dongen, JLJ, et al.. Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions. J\u00a0Pharm Biomed Anal 2022;221:115027. https:\/\/doi.org\/10.1016\/j.jpba.2022.115027.","DOI":"10.1016\/j.jpba.2022.115027"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_023","doi-asserted-by":"crossref","unstructured":"Klak, A, Pauwels, S, Vermeersch, P. Preanalytical considerations in therapeutic drug monitoring of immunosuppressants with dried blood spots. Diagnosis (Berl) 2019;6:57\u201368. https:\/\/doi.org\/10.1515\/dx-2018-0034.","DOI":"10.1515\/dx-2018-0034"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_024","unstructured":"Zakaria, R, Allen, KJ, Koplin, JJ, Roche, P, Greaves, RF. Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. EJIFCC 2016;27:288\u2013317."},{"key":"2026082718023500057_j_cclm-2026-0146_ref_025","doi-asserted-by":"crossref","unstructured":"Verougstraete, N, Stove, CP. Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors. J\u00a0Pharm Biomed Anal 2022;207:114418. https:\/\/doi.org\/10.1016\/j.jpba.2021.114418.","DOI":"10.1016\/j.jpba.2021.114418"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_026","doi-asserted-by":"crossref","unstructured":"De Kesel, PM, Lambert, WE, Stove, CP. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma. Bioanalysis 2014;6:3011\u201324. https:\/\/doi.org\/10.4155\/bio.14.149.","DOI":"10.4155\/bio.14.149"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_027","doi-asserted-by":"crossref","unstructured":"Cobos, PN, Steglich, C, Santer, R, Lukacs, Z, Gal, A. Dried blood spots allow targeted screening to diagnose mucopolysaccharidosis and mucolipidosis. JIMD Rep 2015;15:123\u201332. https:\/\/doi.org\/10.1007\/8904_2014_308.","DOI":"10.1007\/8904_2014_308"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_028","doi-asserted-by":"crossref","unstructured":"Malvagia, S, Ferri, L, Della Bona, M, Borsini, W, Cirami, CL, Dervishi, E, et al.. Multicenter evaluation of use of dried blood spot compared to conventional plasma in measurements of globotriaosylsphingosine (LysoGb3) concentration in 104 Fabry patients. Clin Chem Lab Med 2021;59:1516\u201326. https:\/\/doi.org\/10.1515\/cclm-2021-0316.","DOI":"10.1515\/cclm-2021-0316"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_029","doi-asserted-by":"crossref","unstructured":"Pizzorno, G, Cao, D, Leffert, JJ, Russell, RL, Zhang, D, Handschumacher, RE. Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta (BBA)\u00a0\u2013\u00a0Mol Basis Dis 2002;1587:133\u201344. https:\/\/doi.org\/10.1016\/S0925-4439(02)00076-5.","DOI":"10.1016\/S0925-4439(02)00076-5"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_030","unstructured":"World Anti-Doping Agency. Technical document\u00a0\u2013\u00a0TD2023IDCR: minimum criteria for chromatographic-mass spectrometric confirmation of the identity of analytes for doping control purposes; 2023."},{"key":"2026082718023500057_j_cclm-2026-0146_ref_031","doi-asserted-by":"crossref","unstructured":"Matuszewski, BK, Constanzer, ML, Chavez-Eng, CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS. Anal Chem 2003;75:3019\u201330. https:\/\/doi.org\/10.1021\/ac020361s.","DOI":"10.1021\/ac020361s"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_032","doi-asserted-by":"crossref","unstructured":"Verstraete, J, Stove, C. Patient-centric assessment of thiamine status in dried blood volumetric absorptive microsamples using LC-MS\/MS analysis. Anal Chem 2021;93:2660\u20138. https:\/\/doi.org\/10.1021\/acs.analchem.0c05018.","DOI":"10.1021\/acs.analchem.0c05018"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_033","doi-asserted-by":"crossref","unstructured":"Henricks, LM, Jacobs, BAW, Meulendijks, D, Pluim, D, van den Broek, D, de Vries, N, et al.. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. Br J Clin Pharmacol 2018;84:2761\u20139. https:\/\/doi.org\/10.1111\/bcp.13719.","DOI":"10.1111\/bcp.13719"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_034","doi-asserted-by":"crossref","unstructured":"Launay, M, Raymond, L, Guitton, J, Loriot, MA, Chatelut, E, Haufroid, V, et al.. Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis. Clin Chem Lab Med 2024;62:2415\u201324. https:\/\/doi.org\/10.1515\/cclm-2024-0317.","DOI":"10.1515\/cclm-2024-0317"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_035","doi-asserted-by":"crossref","unstructured":"Yin, F, Ling, Y, Martin, J, Narayanaswamy, R, McIntosh, L, Li, F, et al.. Quantitation of uridine and L-dihydroorotic acid in human plasma by LC-MS\/MS using a surrogate matrix approach. J\u00a0Pharm Biomed Anal 2021;192:113669. https:\/\/doi.org\/10.1016\/j.jpba.2020.113669.","DOI":"10.1016\/j.jpba.2020.113669"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_036","doi-asserted-by":"crossref","unstructured":"McNamara, C. 1 - Collection and handling of blood. In: Bain, BJ, Bates, I, Laffan, MA, editors. Dacie and Lewis practical haematology, 12th ed. 3 London: Elsevier; 2017:1\u20137 pp.","DOI":"10.1016\/B978-0-7020-6696-2.00001-1"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_037","doi-asserted-by":"crossref","unstructured":"Menestrina Dewes, M, L CdS, Fazenda Meireles, Y, Viana de Freitas, M, Frank Bastiani, M, Feltraco Lizot, L, et al.. Evaluation of the Tasso-SST\u00ae capillary blood microsampling device for the measurement of endogenous uracil levels. Clin Biochem 2022;107:1\u20136. https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.06.003.","DOI":"10.1016\/j.clinbiochem.2022.06.003"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_038","doi-asserted-by":"crossref","unstructured":"da Silva, LC, Grando, AP, de Baco, LS, Hahn, RZ, Ferreira Filho, AF, Brucker, N, et al.. Evaluation of dried blood spots as an alternative sampling strategy for 5-fluorouracil monitoring: from method development to clinical application. J\u00a0Pharm Biomed Anal 2023;235:115539. https:\/\/doi.org\/10.1016\/j.jpba.2023.115539.","DOI":"10.1016\/j.jpba.2023.115539"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_039","doi-asserted-by":"crossref","unstructured":"Radovanovic, M, Schneider, JJ, Shafiei, M, Martin, JH, Galettis, P. Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS\/MS. J\u00a0Chromatogr B Analyt Technol Biomed Life Sci 2022;1188:123075. https:\/\/doi.org\/10.1016\/j.jchromb.2021.123075.","DOI":"10.1016\/j.jchromb.2021.123075"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_040","doi-asserted-by":"crossref","unstructured":"Glewis, S, Michael, M, Gurney, H, Olver, I, Zdenkowski, N, Ackland, S, et al.. Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): a multicentre clinical trial. Br J Clin Pharmacol 2025;91:1965\u201374. https:\/\/doi.org\/10.1002\/bcp.70006.","DOI":"10.1002\/bcp.70006"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_041","doi-asserted-by":"crossref","unstructured":"Loison, G, Bouges Le Royer, H, Marsili, S, Brice, A, Vintejoux, J, Yakoubi, M, et al.. Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing. Clin Chem Lab Med 2024;62:e129\u201331. https:\/\/doi.org\/10.1515\/cclm-2023-1096.","DOI":"10.1515\/cclm-2023-1096"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_042","doi-asserted-by":"crossref","unstructured":"Ait Belkacem, I, Mossadegh-Keller, N, Bourgoin, P, Arnoux, I, Loosveld, M, Morange, PE, et al.. Cell analysis from dried blood spots: new opportunities in immunology, hematology, and infectious diseases. Adv Sci (Weinh) 2021;8:e2100323. https:\/\/doi.org\/10.1002\/advs.202100323.","DOI":"10.1002\/advs.202100323"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_043","doi-asserted-by":"crossref","unstructured":"Pani, J, Mohanty, K, Mishra, S, Hasan, T, Purohit, A, Sharma, S, et al.. Heparin or EDTA; anticoagulant of choice in free radical estimation? Oxidants Antioxid Med Sci 2012;1:21\u20134. https:\/\/doi.org\/10.5455\/oams.130512.br.001.","DOI":"10.5455\/oams.130512.br.001"},{"key":"2026082718023500057_j_cclm-2026-0146_ref_044","unstructured":"World Health Organization. WHO guidelines on drawing blood: best practices in phlebotomy. Geneva: World Health Organization; 2010."},{"key":"2026082718023500057_j_cclm-2026-0146_ref_045","doi-asserted-by":"crossref","unstructured":"Capiau, S, Van Landschoot, A, Reyns, T, Stepman, H. Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma. Clin Chem Lab Med 2022;60:e112\u20135. https:\/\/doi.org\/10.1515\/cclm-2021-0921.","DOI":"10.1515\/cclm-2021-0921"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0146\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0146\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:03:02Z","timestamp":1787853782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0146\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,9,25]]}},"alternative-id":["10.1515\/cclm-2026-0146"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0146","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}